Dual-approved PK activator seeks sickle cell label under accelerated approval, contingent on FDA accepting single-arm RISE UP data as the regulatory basis

Agios Pharmaceuticals is a commercial-stage company with an approved drug for blood disorders that now seeks regulatory approval for sickle cell disease, though that sickle cell indication is not yet approved.

Mitapivat already holds approved thalassemia labels in the U.S. and Europe, generating $44.7M in Q2 2026 revenue, and now targets sickle cell disease under accelerated approval with a November 2026 PDUFA date. The thesis turns on whether FDA grants approval on the RISE UP data and whether REIGNITE confirms clinical benefit before any post-market withdrawal risk materializes. The accelerated approval pathway itself is the primary structural risk: single-arm or surrogate-endpoint data could face regulatory skepticism, and tebapivat's dual Phase 2 failures remove a key pipeline buffer.